050620 HITLAB CRO Webcast

[On-Demand Webinar]

Clinical Trials in a Post Pandemic Era

Watch this OnDemand webinar on Future of Clinical Trials in a Post Pandemic era moderated by Professor Stan Kachnowski, Director of the Digital Health Strategy program at Columbia Business School. Joining the panel will be Joris van Dam, Head of Digital Therapeutics at Novartis, Javier Lopez-Molina, Director US Strategy Planning at IQVIA, Bill Taranto, President & General Partner at Merck Global Health Innovation Fund and Jeff Ventimiglia, Senior Vice President, Medidata Solutions.

The panel discusses:

  • Considering the March 2020 FDA Guidance to help industry and investigators navigate the COVID-19 pandemic, what can CROs and Sponsors do now to keep trials on track?
  • How can virtual trials improve patient enrollment, retention, and engagement in a clinical trial?
  • Why does a technology strategy matter for CROs?
  • How much of the future CRO model will be defined by digital solutions?
  • Which emerging technologies will be diffusing the fastest within the CRO community?
  • How will CROs in the future help sponsors make sense of the data and remove barriers so sponsors can access the data in real time?
  • Where will Big Data, Machine Learning and Artificial Intelligence be applied?

Meet the Panel

Joris van Dam
Head of Digital Therapeutics

Joris van Dam is a Digital Health intrapreneur with 16 years’ experience in Pharmaceutical Research & Development, focusing on the innovative use of digital technologies to improve and transform therapeutic innovation, patient engagement, and clinical trials operations. Joris is currently leading the Digital Therapeutics initiative at Novartis Institutes for BioMedical Research, including its collaboration with Pear Therapeutics on the development of novel digital therapies for the treatment of schizophrenia and multiple sclerosis.

Joris holds a PhD in Artificial Intelligence from the University of Amsterdam.

Javier Lopez-Molina
Director US Strategy Planning

Javier began at IQVIA in life sciences consulting, helping to build the first multi-site near-real time real-world evidence platform for non-small cell lung cancer, and is currently responsible for facilitating strategic planning across IQVIA’s US businesses. Prior to joining IQVIA, Javier served as a molecular biologist at Merck and at Stem Centrx, an antibody drug company in San Francisco. He has an MBA from Columbia Business School, a Masters in Biology from MIT, and a Bachelors from Johns Hopkins University.

Bill Taranto
President & General Partner
Merck Global Health Investment Fund

Bill Taranto is the Founder and President of the GHI Fund and responsible for all areas of investing. Bill has more than 30 years of health care experience including over 20 years of healthcare investing. In addition to his experience in venture investing, Bill has more than a decade of management operations experience. Today Mr. Taranto is a member of the Merck Innovative Ventures Board, a group that manages the identification and funding of portfolio businesses; and is also Chairman of the GHI Fund LLC Management Board. Prior to joining Merck, Mr. Taranto spent 18 years at Johnson & Johnson in various venture capital, marketing, sales and business development roles. Before J&J, Mr. Taranto spent eight years in investment banking. Mr. Taranto has a Bachelor of Business Administration from St. Bonaventure University.

Jeff Ventimiglia
Senior Vice President
Medidata Solutions

Jeff Ventimiglia is the Senior Vice President of Product Enablement & Operations at Medidata Solutions. An experienced business executive and life sciences consultant with over 15 years of experience in product management, Life Sciences research, and technology deployment; Jeff has focused on driving better clinical trials through the adoption of platform technology. Mr Ventimiglia’s experience spans from CROs, Pharmaceutical Sponsors, and Clinical Research sites. Jeff received his BSE in Biomedical Engineering from Tulane University and his MM in Clinical Informatics from Duke University Fuqua School of Business.

Dr. Stan Kachnowski
Director, Digital Health Strategy, Columbia Business School

Professor Stan Kachnowski, PhD MPA CSEP, an Oxford trained researcher, has taught over 5,000 students from Columbia University, IIT-Delhi, and Quinnipiac College. His teaching and research over the past 25 years includes educating graduate level and executive students on 4 continents and conducting extensive studies on the efficacy and diffusion of digital health, including electronic data capture, ePRO, wearables, and predictive algorithms. Professor Kachnowski has authored over 200 peer-reviewed papers and presentations for national and international journals and societies in digital health development, management, and diffusion.

Professor Kachnowski holds Bachelors and Master’s Degrees from the University of Vermont, and a Doctorate from the University of Oxford.